Nemaura Medical Retains Paul Kennedy as Advisor for International Growth Opportunities and Member of the Executive Advisory...
March 25 2021 - 8:10AM
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on
developing and commercializing non-invasive wearable
diagnostic devices and supporting personalized lifestyle
coaching programs, today announces that it
has retained Paul Kennedy who will be advising the
Company on its commercial growth initiatives.
“Paul brings a wealth of Bio and Medtech
experience with many years in the industry in different roles
providing a well-rounded background. He spent 15 years at Novo
Nordisk, a biotechnology company that focuses on the discovery of
more effective treatments for people living with diabetes and other
serious chronic diseases, including as CEO of the Company
in France. As a result of Paul’s years of experience in the biotech
industry, he brings with him a large network
that will be invaluable in helping Nemaura in
driving its commercial growth initiatives. We look forward to
working with Paul and are excited to see the impact he
will have in this advisory role,”
said Faz Chowdhury, Ph.D., Nemaura’s CEO.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical
technology company developing and commercializing
non-invasive wearable diagnostic devices. The company
is currently
commercializing sugarBEAT® and proBEAT™. sugarBEAT®,
a CE mark approved Class IIb medical device, is a non-invasive and
flexible continuous glucose monitor (CGM) providing actionable
insights derived from real time glucose measurements and daily
glucose trend data, which may help people with diabetes and
pre-diabetes to better manage, reverse, and prevent the onset
of diabetes. Nemaura has submitted a PMA (Premarket
Approval Application) for sugarBEAT® to the
U.S. FDA. proBEAT™ combines non-invasive
glucose data processed using artificial intelligence
and a digital healthcare subscription service launched in the
USA under the BEATdiabetes.Life program.
The Company sits at the intersection of the
global Type 2diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by
2023.
For more information,
please visit www.NemauraMedical.com.
Cautionary Statement Regarding
Forward-Looking Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the US, risks related to regulatory
status and the failure of future development and preliminary
marketing efforts, Nemaura’s ability to secure additional
commercial partnering arrangements, risks and uncertainties
relating to Nemaura and its partners’ ability to develop,
market and sell proBEAT™, the availability of substantial
additional equity or debt capital to support its research,
development and product commercialization activities, and the
success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to both proBEAT™ digital health,
and sugarBEAT®. There can be no assurance that the company
will be able to reach a part of or any of the global market for CGM
with its products/services. The FDA reserves the right to
re-evaluate their decision that proBEAT™ qualifies as a
general wellness product should it become aware of any issues such
as skin irritation or other adverse events from the device, as well
as any misuse impacting patient safety, and any other reason as the
FDA may see fit at its discretion to determine the product does not
fit the definition of a general wellness product. These and other
risks and uncertainties are identified and described in more detail
in Nemaura’s filings with the United States Securities
and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the most recently completed fiscal year,
its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update
or revise any forward-looking statements.
Contact:
Jules Abraham CORE IR 917-885-7378 julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024